Oral protein delivery: A patent review of academic and industrial approaches

Recent Patents on Drug Delivery and Formulation

Volumn 3, Issue 2, 2009, Pages 94-104

  Werle, Martin ^a   Makhlof, Abdallah ^a   Takeuchi, Hirofumi ^a  

^a GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Oral calcitonin; Oral GLP; Oral insulin; Oral peptide delivery; Oral protein delivery; Oral PTH

Indexed keywords

ALGINIC ACID; APROTININ; BILE SALT; CALCITONIN; CAPSULIN IR; CAPSULIN OAD; CHITOSAN; CYANOCOBALAMIN; CYCLOHEXANEPROPANOIC ACID; EDETIC ACID; ENZYME INHIBITOR; ERYTHROPOIETIN; GLUCAGON LIKE PEPTIDE; GLUCAGON LIKE PEPTIDE 1; GRANULOCYTE COLONY STIMULATING FACTOR; HEPARIN; IN 105; INSULIN; LIPOSOME; N [8 (2 HYDROXYBENZOYL)AMINO]CAPRYLATE; NANOPARTICLE; OCTANOIC ACID; ORADEL; ORMD 0801; PENETRATION ENHANCING AGENT; PEPTIDE; POLYGLUTAMIC ACID; POLYMER; PROPIONIC ACID; PROTEIN; PROTEIN ZO1; RECOMBINANT PARATHYROID HORMONE; SALCATONIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINE; PHARMACEUTICAL VEHICLES AND ADDITIVES;

BIOCOMPATIBILITY; CANCER INHIBITION; CARCINOGENICITY; CHEMICAL STRUCTURE; CLINICAL TRIAL; DIABETES MELLITUS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG COATING; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUSTRY; DRUG MECHANISM; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG RELEASE; DRUG SAFETY; DRUG SYNTHESIS; DRUG TRANSPORT; DRUG UPTAKE; ENZYME DEGRADATION; GLUCOSE BLOOD LEVEL; HUMAN; HYDROPHILICITY; INSULIN DEPENDENT DIABETES MELLITUS; LIGAND BINDING; MEMBRANE DAMAGE; NANOENCAPSULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET CELL HYPERPLASIA; PARTICLE SIZE; PARTICULATE MATTER; PRIORITY JOURNAL; PROTEINASE INHIBITION; REVIEW; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT; CHEMISTRY; INDUSTRY; INTESTINE ABSORPTION; METHODOLOGY; ORAL DRUG ADMINISTRATION; PATENT; PERMEABILITY; PHARMACEUTICS; PHYSIOLOGY;

ADJUVANTS, PHARMACEUTIC; ADMINISTRATION, ORAL; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; ENZYME INHIBITORS; HUMANS; INDUSTRY; INTESTINAL ABSORPTION; PATENTS AS TOPIC; PERMEABILITY; POLYMERS; PROTEINS; TECHNOLOGY, PHARMACEUTICAL;

EID: 68849115881     PISSN: 18722113     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221109788452221     Document Type: Review

References (75)

1. Damgé C, Reis CP, Maincent P. Nanoparticle strategies for the oral delivery of insulin. Expert Opin Drug Deliv 2008; 5(1): 45-68.
2. Swarbrick J, Boylan JC. Encyclopedia of Pharmaceutical Technology 2nd ed. New York, Marcel Dekker 2002; 885.
3. Woodley JF. Enzymatic barriers for gi peptide and protein delivery. Crit Rev Ther Drug Carrier Syst 1994; 11 (2-3): 61-95.
4. http://www.emisphere.com
5. http://www.diabetology.co.uk
6. http://www.oramed.com
7. http://www.unigene.com
8. Brayden DJ, Jepson MA, Baird AW. Keynote review: Intestinal Peyer's patch M cells and oral vaccine targeting. Drug Discov Today 2005; 10: 1145-1157.
9. Shahiwala A, Vyas TK, Amiji MM. Nanocarriers for systemic and mucosal vaccine delivery. Recent Pat Drug Deliv Form 2007; 1: 1-9
10. Florence AT. The oral absorption of micro- and nanoparticulates: Neither exceptional nor unusual. Pharm Res 1997; 14 (3): 259-266.
11. Jani P, Halbert GW, Langridge J, Florence AT. Nanoparticle uptake by the rat gastrointestinal mucosa: Quantitation and particle size dependency. J Pharm Pharmacol 1990; 42 (12): 821-826.
12. Sung, H., Lin, Y., Tu, H.: US20090011008 (2009).
13. Reis, C.P., Veiga, F.J., Ribeiro, A.J., Neufeld, R.J.: WO2007129926 (2007).
14. Reis, C.P., Veiga, F.J., Ribeiro, A.J., Neufeld, R.J., Damge, C.: WO2008051101 (2008).
15. Sharma, C.P., Mannemcherril, R.R.: WO2007032018 (2007).
16. Ishizuno, A., Imanaka, H., Ando, H., Makino, T.: JP171262 (2003).
17. Dean, H.J., Brey, R.N., Boloten, E., Bucher, D., Frenchick P.J.: WO0076476 (2000).
18. Badwan, A.A., Al-Remawi, M., El-Thaher, T., Elsayed, A.: EP1797870 (2007).
19. Seliguchi, Y., Shimizu, N., Nagai, T., Morishita, M.: JP10330287 (1998).
20. Leroux, J.C., Jones, M.C., Tewari, P.K.: WO2006105659 (2006).
21. Allémann E, Leroux J, Gurny R. Polymeric nano- and microparticles for the oral delivery of peptides and peptidomimetics. Adv Drug Deliv Rev 1998; 34: 171-189.
22. Maincent, P., Ubrich. N., Vigneron, C.: WO0203960 (2002).
23. Bernkop-Schnürch A, Walker G. Multifunctional matrices for oral peptide delivery. Crit Rev Ther Drug Carrier Syst 2001; 18: 459-501.
24. Luessen HL, de Leeuw BJ, Langemeÿer MW, de Boer AB, Verhoef JC, Junginger HE. Mucoadhesive polymers in peroral peptide drug delivery. VI Carbomer and chitosan improve the intestinal absorption of the peptide drug buserelin in vivo. Pharm Res 1996; 13:1668-1672.
25. Luessen HL, Verhoef JC, Borchard G, Lehr CM, de Boer AG, Junginger HE. Mucoadhesive polymers in peroral peptide drug delivery. II. Carbomer and polycarbophil are potent inhibitors of the intestinal proteolytic enzyme trypsin. Pharm Res 1995; 12: 1293-1298.
26. Tanaka, T., Ilmain, F., Kokufuta, E., Annaka, M.: US5403893 (1995).
27. Sung, H.W., Chen, M.C., Lee, P.W., Tu, H.: US20087449200 (2008).
28. Touitou E, Barry BW. Inhibition of enzymes and secretory transport; In: Enhancement in drug delivery. CRC Press, Taylor Francis 2006; 85-111.
29. Bernkop-Schnürch A. The use of inhibitory agents to overcome the enzymatic barrier to perorally administered therapeutic peptides and proteins. J Control Release 1998; 52 (1-2): 1-16.
30. Kidron, M., Ziv, E., Bar-On, H., Eldor, A.: US4579730 (1986).
31. Desai, A.J.: US5206219 (1993).
32. Melmed RN, El-Aaser AA, Holt SJ. Hypertrophy and hyperplasia of the neonatal rat exocrine pancreas induced by orally administered soybean trypsin inhibitor. Biochim Biophys Acta 1976; 421(2): 280-288.
33. Bernkop-Schnürch, A., Paikl, C.: WO9831712 (1998).
34. Brinckerhoff LH, Kalashnikov VV, Thompson LW, et al. Terminal modifications inhibit proteolytic degradation of an immunogenic MART-1(27-35) peptide: Implications for peptide vaccines. Int J Cancer 1999; 83 (3): 326-334.
35. Powell MF, Stewart T, Otvos L Jr, et al. Peptide stability in drug development. II. Effect of single amino acid substitution and glycosylation on peptide reactivity in human serum. Pharm Res 1993; 10(9): 1268-1273.
36. Werle M, Schmitz T, Huang HL, Wentzel A, Kolmar H, Bernkop-Schnürch A. The potential of cystine-knot microproteins as novel pharmacophoric scaffolds in oral peptide drug delivery. J Drug Target 2006; 14(3): 137-146.
37. Pei Z. From the bench to the bedside: Dipeptidyl peptidase IV inhibitors, a new class of oral antihyperglycemic agents. Curr Opin Drug Discov Dev 2008; 11(4): 512-532.
38. Khafagy E, Morishita M, Onuki Y, Takayama K. Current challenges in non-invasive insulin delivery systems: A comparative review. Adv Drug Deliv Rev 2007; 59: 1521-1546.
39. Aungst BJ. Intestinal permeation enhancers. J Pharm Sci 2000; 89: 429-442.
40. Mahato RI, Narang AS, Thoma L, Miller DD. Emerging trends in oral delivery of peptide and proteins. Crit Rev Ther Drug Carr Syst 2003; 20: 153-214.
41. Stern, W.: US2007134279 (2007).
42. Salama NN, Fasano A, Lu R, Eddington ND. Effect of the biologically active fragment of zonula occludens toxin, delta G, on the intestinal paracellular transport and oral absorption of mannitol. Int J Pharm 2003; 251(1-2): 113-121.
43. Sahni JK, Chopra S, Ahmad FJ, Khar RK. Potential prospects of chitosan derivative trimethyl chitosan chloride (TMC) as a polymeric absorption enhancer: Synthesis, characterization and applications. J Pharm Pharmacol 2008; 60(9): 1111-1119.
44. Yen WC, Lee VHL. Penetration enhancement effect of Pz-peptide, a paracellularly transported peptide, in rabbit intestinal segments and Caco-2 cell monolayers. J Control Rel 1995; 36: 25-37.
45. http://www.biocon.com
46. http://www.thiomatrix.com
47. http://www.apollolifesciences.com
48. Chalasani, K.B., Diwan, P.V., Raghavan K.V., Russell-Jones G.J., Jain, S.K., Rao K K.: US2002192235 (2002).
49. Russell-Jones, G.J., Westwood, S.W.: US20016262253 (2001).
50. Petrus AK, Vortherms AR, Fairchild TJ, Doyle RP. Vitamin B12 as a carrier for the oral delivery of insulin. Chem Med Chem 2007; 2(12): 1717-1721.
51. Doyle, R.P.: US20080242595 (2008).
52. Russell-Jones, G. J., Mcewan, J.: US20060127310 (2006).
53. Russell-Jones, G.J., Mcewan, J.: WO0066090 (2000).
54. Raw, K.K.: WO2007113665 (2007).
55. Leone-Bay, A., Santiago, N.B.: US5541155 (1996).
56. Leone-Bay, A., Nai, F.W.: US5935601 (1999).
57. Qi R, Ping QN, Zhao W. Studies on gastrointestinal absorption enhancement effect and mechanism of sodium N-[8-(2-hydroxybenzyl)amino] caprylate to insulin solution. Yao Xue Xue Bao 2003; 38 (12): 953-956.
58. Malkov D, Angelo R, Wang HZ, Flanders E, Tang H, Gomez-Orellana I. Oral delivery of insulin with the eligen technology: Mechanistic studies. Curr Drug Deliv 2005; 2 (2): 191-197.
59. Bay, W.E., Agarwal, R.K., Chaudhary, K., Shingai M., Goldberg, M.M., Corvino, J.P., Azria, M., Ault, J.M., Bateman, S.D., Patel, S., Sikora, J., Yang, R.F., Zielinski, J.L.: US20080269134 (2008).
60. Bernkop-Schnürch, A.: EP1126881 (2001).
61. Grabovac V, Guggi D, Bernkop-Schnürch A. Comparison of the mucoadhesive properties of various polymers. Adv Drug Deliv Rev 2005; 57(11): 1713-1723.
62. Werle M, Bernkop-Schnürch A. Thiolated chitosans: Useful excipients in oral drug delivery. J Pharm Pharmacol 2008; 60(3): 273-281.
63. Deutel B, Greindl M, Thaurer M, Bernkop-Schnürch A. Novel insulin thiomer nanoparticles: in vivo Evaluation of an oral drug delivery system. Biomacromolecules 2008; 9 (1): 278-285.
64. Ekwuribe, N.N.: US5359030 (1994).
65. Radhakrishnan, B., Aggarwal, D., Ferro, M., James, K.D., Malkar, N.B., Miller, M.A., Pavliv, L., Polowy, K., Puskas, K., Ekwuribe, N.N.: WO2006014673 (2006).
66. Ekwuribe, N.N., Price, C.H., Ansari, A.M., Radhakrishnan, B.O., Amy, L: US20067084114 (2006).
67. Ekwuribe, N.N., Radhakrishnan, B.: WO2004043347 (2004).
68. New Roger, R.C.: EP1326644 (2003).
69. New Roger, R.C.: EP1620073 (2006).
70. New Roger, R.C.: EP1613355 (2006).
71. Russell-Jones, G.J., Luke, M.R.: AU250536 (2007).
72. Kidron, M.: EP1933862 (2008).
73. Stern, W., Gilligan, J.P.: US5912014 (1999).
74. Stern, W., Gilligan, J.P.: US20006086918 (2000).
75. Stern, W., Mehta, N.M., Ray, M.V.L.: US20046673574 (2004).